Abstract: The present disclosure describes multivalent antibacterial vaccines for the treatment of bacterial infections, such as Klebsiella, E. coli and E. cloacae, as well as therapy-resistant forms thereof.

Abstract: An acoustical non-contact levitation system and method for eliciting the deformation response of biological samples, coupled with the data analysis to yield quantitative measures of established time-dependent viscoelastic material properties. Embodiments allow for measurement to occur in near-real-time by way of a computer. In use, a biological sample is placed in an acoustic levitator, where it is induced to oscillate, such that material properties of the sample can be observed and analyzed by way of a camera and/or photodiode.

Abstract: Surfactants are imbibed into Halloysite nanotubes (HNT) and the imbibed nanotubes are coated with wax on the nanotube outer surface. The wax layer prevents the surfactant from being disgorged from the HNT lumen until a triggering condition exists. Triggering conditions include contact with oil, which dissolves the wax; or exposure to temperatures above a melt transition of the wax, which causes the wax to melt. Upon exposure to a triggering condition, at least some of the imbibed surfactants are disgorged from the HNT and into the surrounding environment. The disgorged surfactants provide a conventional effect of reducing interfacial tension and changing reservoir rock wettability to enhance oil recovery. A range of surfactants and waxes are usefully employed in the compositions and methods described herein.

Abstract: The invention provides devices for supporting regeneration of body tissue and of tubular structures, such as the esophagus or intestine, and methods for making and for using the devices.

Abstract: The present disclosure provides CRISPR-based compositions and methods of their use to impair or promote angiogenesis in a patient to treat indications including, but not limited to, tumor growth, age-related macular degeneration, and metastasis.

Abstract: Described herein are membrane permeabilizing peptides and antimicrobial peptides, polynucleotides encoding the peptides, and compositions containing the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and compositions for research, diagnosis, and therapy.

Abstract: A method for treating opioid use disorder comprises administering to a subject a pharmaceutical composition comprising a cyclic peptide of Formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier; wherein the peptide of formula X1-c[X2-X3-Phe-X4]-X5 is administered in place of, and as a substitute for an opioid to which the subject is addicted. X1 is Tyr or 2,6-Dmt; X2 is an acidic or basic D-amino acid; X3 is Trp or Phe; there is an amide bond between the sidechains of X2 and X4; X5 is NHR (R=H or alkyl) or an amino acid amide. When X2 is an acidic D-amino acid, X4 is a basic amino acid, X3 is Phe, and X5 is NHR; and when X2 is a basic D-amino acid, X4 is an acidic amino acid, and X3 is Trp.

Abstract: Provided are synthetic dendrimer calibrants for mass spectrometry. The calibrants are distinguished by their relative case and rapidity of synthesis, comparatively low cost, long shelf life, high purity, and amenability to batch synthesis as mixtures. The latter characteristic enables parallel preparation of higher molecular weight compounds displaying useful distributions of discrete molecular weights, thereby providing multi-point mass spectrometry calibration standards. Methods of making, tuning and using said calibrants are provided.

Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are trasfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IF?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.

Abstract: Disclosed herein are precursor compounds, composite electrodes comprising the same, and methods of making and use thereof.

Abstract: Described herein are membrane permeabilizing peptides, polynucelotides encoding the peptides, and lipid vesicles comprising the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and lipid vesicles for research, diagnosis, disease prevention, and therapeutic treatment.

Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.

Abstract: A variety of hydrophobically modified polypeptoids are provided. The hydrophobically modified polypeptoids can include a polyamide backbone having a random copolymer of two or more different types of repeat units, where one or more of the repeat units have nitrogen atom having a hydrophobic substituent attached thereto. Methods of making the hydrophobically modified polypeptoids are also provided, as well as uses of the hydrophobically modified polypeptoids, for example in liposomal drug delivery.

Abstract: The use of photovoltaic (PV) cells to convert solar energy to electricity is becoming increasingly prevalent; however, there are still significant limitations associated with the widespread adoption of PV cells for electricity needs. There is a clear need for a high efficiency solar power system that supplies electricity at a competitive cost and that provides for an on-demand supply of electricity as well as energy storage. By combining aspects of concentrated solar power and concentrated photovoltaics, the present invention provides a device that enables the conversion of sunlight to electricity at very high efficiencies and that enables the transmission of thermal energy to heat storage devices for later use. The disclosed device enables transmissive CPV through the use of a multijunction PV cell mounted on a transparent base. The use of a multijunction cell allows for highly efficient absorption of light above the bandgap of the lowest bandgap subcell.

Abstract: Embodiments herein implement quantum annealing with a driver Hamiltonian that uses oscillating fields to advantageously obtain a quantum speedup over classical computing techniques. For a many-body quantum system formed with qubits, the oscillating fields drive the qubits so as to independently modulate the magnitudes and/or directions of transverse terms of the driver Hamiltonian. In particular, embodiments provide a quantum speedup for two types of first-order phase transitions: the paramagnet-to-spin-glass transition, and transitions between distinct “bit string” states. The resulting speedup is robust against energy fluctuations (e.g., 1/f noise), in contrast to other strategies like variable-rate annealing. Each oscillating field may be an oscillating electric field or magnetic field. The oscillating fields can be implemented with superconducting flux qubits by coupling oscillating fluxes and/or voltages to the flux qubits.

Abstract: Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.

Abstract: The present invention discloses the morphology of hollow, double-shelled submicrometer particles generated through a rapid aerosol-based process. The inner shell is an essentially hydrophobic carbon layer of nanoscale dimension (5-20 nm), and the outer shell is a hydrophilic silica layer of approximately 5-40 nm, with the shell thickness being a function of the particle size. The particles are synthesized by exploiting concepts of salt bridging to lock in a surfactant (CTAB) and carbon precursors together with iron species in the interior of a droplet. This deliberate negation of surfactant templating allows a silica shell to form extremely rapidly, sealing in the organic species in the particle interior. Subsequent pyrolysis results in a buildup of internal pressure, forcing carbonaceous species against the silica wall to form an inner shell of carbon. The incorporation of magnetic iron oxide into the shells opens up applications in external stimuli-responsive nanomaterials.

Abstract: The invention provides compositions and methods for reducing symptoms of inflammation by administering therapeutically effective amounts of (a) (1) enterotoxic E. coli heat labile detoxified toxin A subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or (2) A1 subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or both (1) and (2), and (b) a carrier that causes internalization of the A subunit or A1 subunit, or both, into cells.

Abstract: The invention is directed to antibody compositions that specifically bind to polycyclic aromatic hydrocarbons (PAHs) and kits encompassing the same.

Abstract: Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be 5 used as adjuvants in compositions and methods to potentiate the immune response to immunogens.